Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06681337

Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of combination therapy for refractory lupus nephritis using universal CAR-T cells targeting BCMA and CD19.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-65 years; both genders eligible.
  • Subjects diagnosed with lupus nephritis.
  • Previous treatment outcomes were unsatisfactory.
  • Diagnosis of active nephritis type III or IV with or without type V according to 2018 International Society of Nephrology and Society of Renal Pathology (ISN/RPS) criteria.
  • NIH Activity Index > 2 and elevated chronicity index.
  • Urine protein: creatinine ratio (UPCR) ≥ 1.0 g/g, or 24-hour urine protein ≥ 1.0 g, with or without active urine sediment with red blood cell casts.
  • Receiving hormones with or without antimalarials.
  • SLEDAI-2K score ≥ 6.
  • Antinuclear antibody positive, and/or anti-ds-DNA antibody positive, and/or anti-Smith antibody positive.
  • Positive expression of CD19 on B cells in peripheral blood.
  • Agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication.
  • Provides written informed consent.

Exclusion criteria

  • History of solid organ transplantation.
  • Malignant tumor within the last two years.
  • Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb), with peripheral blood Hepatitis B virus (HBV) DNA detected as positive; positive for Hepatitis C virus antibodies, with peripheral blood Hepatitis C virus RNA detected as positive; positive for Human Immunodeficiency Virus (HIV) antibodies; positive for Cytomegalovirus (CMV) DNA; positive for syphilis.
  • Primary immunodeficiency (congenital or acquired).
  • Severe cardiac disease.
  • History of psychiatric disorders or history of psychotropic drug abuse, with no history of withdrawal.
  • Allergic constitution or a history of severe allergies.
  • Pregnant or breastfeeding women.

Treatment and study plan

BCMA CART + CD19 CART

Biological

BCMA CART + CD19 CART

Primary outcomes

  1. AEs

    Time frame: Within 6 months after BCMA CART and CD19 CART infusion

    The total number, incidence, and severity of AE

Secondary outcomes

  1. ORR (CR and PR)

    Time frame: At 6 months after BCMA CART and CD19 CART infusion

    Complete response (CR) was defined as serum creatinine ≤ 1.2 mg/dl or ≤ 125% of baseline value, and urine protein/creatinine ratio < 0.5 or 24-hour urine protein quantification < 0.5 g, and prednisone dose reduction to ≤ 10 mg/d (or equivalent dose). Partial response (PR) was defined as if both serum creatinine and urine protein/creatinine ratio (or 24-hour urine protein quantification) were abnormal before treatment, both items improved by > 30% after treatment, without other indicators of deterioration; if only urine protein/creatinine ratio (or 24-hour urine protein quantification) was abnormal before treatment, the improvement was > 50% after treatment.

Other outcomes

  1. PK/PD

    Time frame: Within 3 months after BCMA CART and CD19 CART infusion

    Changes and duration of CAR gene copy number and CAR-T cell number in peripheral blood after BCMA CART and CD19 CART infusion

Study contacts

Contact information is provided by the study sponsor or research team.

Dandan Wang, PhD

CONTACT

[email protected]

15850515316

Sponsors and collaborators

Lead sponsor

Bioray Laboratories

Industry

Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Registry information

Official study title

A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 8, 2024
Registry last updated
Nov 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.